Wyeth looks to Synmetrics to enhance its target profiling

27 August 2006

Wyeth Pharmaceuticals has signed a new three-year agreement with Dendrite for the use of its Synmetrics four character pressure profiling system. This approach will enable Wyeth to personalize its marketing to general practitioners and ensure it targets them more effectively.

Synmetrics Profiling produces its four-character code by comparing the "pressure" on each GP in the four target areas; calls, meetings, receipt of direct mail, response to direct mail, against those on his or her peers, determined by the wealth of data that is sent back to Dendrite by its many pharmaceutical clients every year. This means that a GP with an ABDH code would be in the top category (12.5%) for targeted calls, the second category for attendance at meetings; the fourth category for the receipt of mailings but in the lowest category when it comes to responding to mailings, says Dendrite. This profiling method will be used alongside three other metrics provided by Dendrite, comprising the best day to visit, target call frequency and its median call frequency.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight